Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Biosimilars Acting Director Yim Is ‘Not A Great Fan’ Of Suffix-Based Naming Policy

Executive Summary

Whether one accepts the view that concerns about active pharmacovigilance and the need to distinguish small molecules from biologics support the controversial nomenclature system is ‘a personal thing,’ Sarah Yim says.

Advertisement

Related Content

Woodcock: Concerns About US FDA's Biosimilars Suffix Policy Detached From Reality
Policy Reversal: FDA Will No Longer Require Suffixes For Older Biologics
FDA Biosimilars Chief Leah Christl Joining Amgen; Agency Veteran Sarah Yim Takes Her Place
Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting
Suffix Smackdown: Gottlieb Calls Issue 'Red Herring' For Biosimilars
First Three Novel Biologic Suffixes Came Courtesy Of US FDA, Not Sponsors
FDA’s Burden Estimate On Biologic Naming Ignores Downstream Costs, Critics Say
Biologic Product Naming: US FDA Sticks With Suffixes ‘Devoid Of Meaning’
FDA Biosimilar Naming Proposal Pits Providers, Patients Against Insurers, Pharmacies
FDA's Biologics Naming Plan: Industry Wants 'Memorable' Suffixes

Topics

Related Companies

What to read next

Advertisement
UsernamePublicRestriction

Register

GB140309

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel